Primary Myelofibrosis Epidemiology Forecast

DelveInsight's 'Primary Myelofibrosis - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Primary Myelofibrosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Primary Myelofibrosis Understanding

The DelveInsight Primary Myelofibrosis epidemiology report gives a thorough understanding of the Primary Myelofibrosis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Primary Myelofibrosis in the US, Europe, and Japan. The report covers the detailed information of the Primary Myelofibrosis epidemiology scenario in seven major countries (US, EU5, and Japan).


Primary Myelofibrosis Epidemiology Perspective by DelveInsight

The Primary Myelofibrosis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Primary Myelofibrosis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Primary Myelofibrosis epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Primary Myelofibrosis Detailed Epidemiology Segmentation

The Primary Myelofibrosis epidemiology covered in the report provides historical as well as forecasted Primary Myelofibrosis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Primary Myelofibrosis report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Primary Myelofibrosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Primary Myelofibrosis Epidemiology Report and Model provide an overview of the risk factors and global trends of Primary Myelofibrosis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Primary Myelofibrosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Primary Myelofibrosis
  • The report provides the segmentation of the Primary Myelofibrosis epidemiology


Report Highlights

  • 11-Year Forecast of Primary Myelofibrosis epidemiology
  • 7MM Coverage
  • Total Cases of Primary Myelofibrosis
  • Total Cases of Primary Myelofibrosis according to segmentation
  • Diagnosed cases of Primary Myelofibrosis


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Primary Myelofibrosis?
  • What are the key findings pertaining to the Primary Myelofibrosis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Primary Myelofibrosis across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Primary Myelofibrosis?
  • What are the currently available treatments of Primary Myelofibrosis?


Reasons to buy

  • The Primary Myelofibrosis Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Primary Myelofibrosis market
  • Quantify patient populations in the global Primary Myelofibrosis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Primary Myelofibrosis therapeutics in each of the markets covered
  • Understand the magnitude of Primary Myelofibrosis population by its epidemiology
  • The Primary Myelofibrosis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Primary Myelofibrosis

3. Primary Myelofibrosis: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Primary Myelofibrosis Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Primary Myelofibrosis Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Primary Myelofibrosis Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Primary Myelofibrosis Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Primary Myelofibrosis Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Primary Myelofibrosis Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Primary Myelofibrosis Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Primary Myelofibrosis Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Primary Myelofibrosis Treatment and Management

6.2. Primary Myelofibrosis Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Primary Myelofibrosis Epidemiology in 7MM (2017-2030)

Table 2 Primary Myelofibrosis Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Primary Myelofibrosis Epidemiology in the United States (2017-2030)

Table 4 Primary Myelofibrosis Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Primary Myelofibrosis Epidemiology in Germany (2017-2030)

Table 6 Primary Myelofibrosis Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Primary Myelofibrosis Epidemiology in France (2017-2030)

Table 8 Primary Myelofibrosis Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Primary Myelofibrosis Epidemiology in Italy (2017-2030)

Table 10 Primary Myelofibrosis Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Primary Myelofibrosis Epidemiology in Spain (2017-2030)

Table 12 Primary Myelofibrosis Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Primary Myelofibrosis Epidemiology in the United Kingdom (2017-2030)

Table 14 Primary Myelofibrosis Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Primary Myelofibrosis Epidemiology in Japan (2017-2030)

Table 16 Primary Myelofibrosis Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Primary Myelofibrosis Epidemiology in 7MM (2017-2030)

Figure 2 Primary Myelofibrosis Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Primary Myelofibrosis Epidemiology in the United States (2017-2030)

Figure 4 Primary Myelofibrosis Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Primary Myelofibrosis Epidemiology in Germany (2017-2030)

Figure 6 Primary Myelofibrosis Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Primary Myelofibrosis Epidemiology in France (2017-2030)

Figure 8 Primary Myelofibrosis Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Primary Myelofibrosis Epidemiology in Italy (2017-2030)

Figure 10 Primary Myelofibrosis Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Primary Myelofibrosis Epidemiology in Spain (2017-2030)

Figure 12 Primary Myelofibrosis Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Primary Myelofibrosis Epidemiology in the United Kingdom (2017-2030)

Figure 14 Primary Myelofibrosis Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Primary Myelofibrosis Epidemiology in Japan (2017-2030)

Figure 16 Primary Myelofibrosis Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Primary Myelofibrosis Epidemiology
  • Primary Myelofibrosis
  • Primary Myelofibrosis Pipeline
  • Primary Myelofibrosis Companies
  • Primary Myelofibrosis prevalent po...
  • Primary Myelofibrosis incident pop...
  • Primary Myelofibrosis patients dia...
  • Primary Myelofibrosis treatment al...

Forward to Friend

Need A Quote